Poland· PL-100438207
Fingolimod Bluefish
A fingolimod product containing fingolimodum, registered in Poland by Bluefish Pharmaceuticals AB. The same ATC class is registered in 3 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Fingolimod is registered in 3 of 19 countries.
Countries holding a registration under ATC L04AA27 (fingolimod), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 2 of them publish a price we can compare per daily dose
Fingolimod · ATC L04AA27
3 / 19 countries
- Belgiumprice
- Ireland
- Polandprice
The record
At a glance
URPL (Poland)- Active substance
- Fingolimodum
- Manufacturer
- Bluefish Pharmaceuticals AB
- Country
- Poland (PL)
- ATC code
- L04AA27
- ATC class
- Fingolimod
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 4
- gtin05909991481803
- gtin05909991481810
- gtin05909991481827
- gtin05909991481834
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
584 interactions on record for fingolimod.
Graded by severity as the source publishes them — 503 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Fingolimod · interactions on record
584 records
- 503 severe
- 77 moderate
- 4 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Fingolimod in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaARELEPTANPharmaselect International Beteiligungs GmbH, Vídeň
- SpainFINGOLIMOD ACCORD 0,5 mg CAPSULAS DURAS EFGAccord Healthcare S.L.U.
- NetherlandsChantico 0,5 mg harde capsulesG.L. Pharma GmbH
- United StatesfingolimodGlenmark Pharmaceuticals Inc., USA
- FinlandAreleptanPharmaselect International Beteiligungs GmbH
- SwedenAreleptan 0,5 mg Kapsel, hårdPharmaselect International Beteiligungs GmbH
- United KingdomFingolimod 500microgram capsulesA A H Pharmaceuticals Ltd
- SwitzerlandFingolimod Devatis
Authorised across Europe · EMA
The same active substance is authorised in 30 EEA countries. Names it is sold under:
- Austria · Areleptan, Chantico
- Belgium · Fingolimod Ab, Fingolimod Eg
- Bulgaria · Chantico, Inzolfi
- Cyprus · Fingolimod Adelco, Fingolimod Remedica
- Czechia · Areleptan, Bonaxon
- Germany · Fingod, Fingolimod 123 Acurae Pharma
- Denmark · Areleptan, Bonaxon
- Estonia · Chantico, Efigalo
- Spain · Fingolimod, Fingolimod Aurovitas
- Finland · Fingolimod, Fingolimod Avansor
- France · Fingolimod Arrow, Fingolimod Benta
- United Kingdom (Northern Ireland) · Fingolimod, Fingolimod Amarox
- Greece · Fingolimod Adelco, Fingolimod Medochemie
- Croatia · Areleptan, Arlesias
- Hungary · Bonaxon, Chantico
- Ireland · Fingolimod Clonmel, Fingolimod Flynn Pharma
- Iceland · Fingolimod, Fingolimod Accord
- Italy · Fingolimod Aurobindo, Fingolimod Dr. Reddy’s
- Liechtenstein · Fingolimod Accord, Fingolimod Mylan
- Lithuania · Chantico, Efigalo
- Luxembourg · Fingolimod Eg, Fingolimod Ratiopharm
- Latvia · Bonaxon, Chantico
- Malta · Fingolimod Denk, Fingolimod Remedica
- Netherlands · Chantico, Fenoxa
- Norway · Areleptan, Fingolimod Accord
- Portugal · Bluesar, Fingolimod Bluefish
- Romania · Fingolimod Dr. Reddys, Fingolimod Msn
- Sweden · Areleptan, Fingolimod Amarox
- Slovenia · Areleptan, Arlesias
- Slovakia · Areleptan, Bonaxon
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b6057782-9208-4791-9f48-cb6e64c844e1 GET /v1/drugs/b6057782-9208-4791-9f48-cb6e64c844e1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Kapsułki twarde",
"source": "urpl",
"strength": "0,5 mg",
"packaging": "05909991481803 ¦ Rpz ¦ 144765\n28 kaps.\n05909991481810 ¦ Rpz ¦ 144766\n98 kaps.\n05909991481827 ¦ Rpz ¦ 144767\n28 kaps.\n05909991481834 ¦ Rpz ¦ 144768\n98 kaps.",
"substance": "Fingolimodum 0.5 mg",
"common_name": "Fingolimodum",
"pl_product_id": "100438207",
"pozwolenie_nr": "27050",
"auth_procedure": "DCP",
"authorisation_validity": "2026-07-09"
}See everything about fingolimod.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.